Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 9/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074306 | 0.87 | MAOB (0.46) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL9076881 | 0.86 | MAOB (0.62) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL20165396 | 0.83 | MAOB (0.63) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL3900510 | 0.83 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2223184 | 0.83 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL69391 | 0.83 | MAOB (0.58) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL6237067 | 0.80 | MAOB (0.54) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL3592598 | 0.80 | MAOB (0.54) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL10364085 | 0.80 | MAOB (0.54) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL2953711 | 0.80 | GRM5 (0.57) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836077-B | Oxazaspiro derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| CN-113754685-B | Dihydrothiochromene pyrazole derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-4190789-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| CN-115835863-A | Oxaazabicyclic derivatives, preparation method and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-110698456-B | Synthesis method of 2, 3-dihydrothiochromen-4-one and derivatives thereof | 重庆医药高等专科学校 | 2021-05-14 | — | — | CN | disclosed |
| CN-110698456-A | Synthesis method of 2, 3-dihydrothiochromen-4-one and derivatives thereof | 重庆医药高等专科学校 | 2020-01-17 | — | — | CN | disclosed |
| US-7384960-B2 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20050192332-A1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | US | disclosed |
| US-6906080-B1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2005-06-14 | — | — | US | disclosed |
| US-4468404-A | MICROBIOCIDES | SCHERING CORPORATION (US) | 1984-08-28 | — | — | US | disclosed |
| US-4431816-A | FUNGICIDES; BACTERICIDES | SCHERING CORPORATION (US) | 1984-02-14 | — | — | US | disclosed |
| US-4352808-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SCHERING CORPORATION (US) | 1982-10-05 | — | — | US | disclosed |
| EP-0054233-A1 | Novel benzo(b)thiophenes, benzo(b)furans, thiochromans and chromans, processes for their preparation and antimicrobial compositions containing them | SCHERING CORPORATION (US) | 1982-06-23 | — | — | EP | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | MAOB 1445/4885MAOA 1720/4885GRM5 2584/4885 |
| US-20050192332-A1 | Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same | CNR1, CNR2, CBR3 | MAOB 1296/4885MAOA 1757/4885GRM5 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.